3SOF

another site for info and learning and strategies
http://biz.yahoo.com/opt/ which might be powered somewhat by optionetics.

Hi,

Buying August calls for Tuesday.

Usually do not hold into a cc, but this time is different, imo.

Chart is setting up very well.

 

Revenue from Nexavar, one of the company's newest products, jumped by 160 percent to 60 million euros. Recent studies showed that the product is the first drug to prolong survival in kidney cancer patients. Rivaroxaban, an anti-clotting drug, was shown to be safer and more effective than a competing treatment, pushing up the share price.

http://www.bloomberg.com/apps/news?pid=20601087&sid=aE.VVf_dz2_I&refer=home